The adaptor protein TRIP6 antagonizes fas-induced apoptosis but promotes its effect on cell migration

Molecular and Cellular Biology

Volumn 30, Issue 23, 2010, Pages 5582-5596

  Lai, Yun Ju ^a,b   Lin, Victor T G ^a   Zheng, Ying ^a   Benveniste, Etty N ^a   Lin, Fang Tsyr ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NATIONAL TAIWAN NORMAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ADAPTOR PROTEIN; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; LYSOPHOSPHATIDIC ACID; PROTEIN TRIP6; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; GENE ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN INTERACTION;

ACTINS; ACTIVE TRANSPORT, CELL NUCLEUS; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIGENS, CD95; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; GLIOMA; HEK293 CELLS; HUMANS; LYSOPHOSPHOLIPIDS; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTORS; TYROSINE;

EID: 78649738475     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00134-10     Document Type: Article

References (49)

1. Ahn, J. H., S. M. Park, H. S. Cho, M. S. Lee, J. B. Yoon, J. Vilcek, and T. H. Lee. 2001. Non-apoptotic signaling pathways activated by soluble Fas ligand in serum-starved human fibroblasts. Mitogen-activated protein kinases and NF-kappaB-dependent gene expression. J. Biol. Chem. 276:47100-47106.
2. Barnhart, B. C., P. Legembre, E. Pietras, C. Bubici, G. Franzoso, and M. E. Peter. 2004. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J. 23:3175-3185.
3. Beier, C. P., and J. B. Schulz. 2009. CD95/Fas in the brain - not just a killer. Cell Stem Cell 5:128-130.
4. Boldin, M. P., T. M. Goncharov, Y. V. Goltsev, and D. Wallach. 1996. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 85:803-815.
5. Chastre, E., M. Abdessamad, A. Kruglov, E. Bruyneel, M. Bracke, Y. Di Gioia, M. C. Beckerle, F. van Roy, and L. Kotelevets. 2009. TRIP6, a novel molecular partner of the MAGI-1 scaffolding molecule, promotes invasiveness. FASEB J. 23:916-1028.
6. Chen, L., S. M. Park, A. V. Tumanov, A. Hau, K. Sawada, C. Feig, J. R. Turner, Y. X. Fu, I. L. Romero, E. Lengyel, and M. E. Peter. 2010. CD95 promotes tumour growth. Nature 465:492-496.
7. Chinnaiyan, A. M., K. O'Rourke, M. Tewari, and V. M. Dixit. 1995. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81:505-512.
8. Corsini, N. S., I. Sancho-Martinez, S. Laudenklos, D. Glagow, S. Kumar, E. Letellier, P. Koch, M. Teodorczyk, S. Kleber, S. Klussmann, B. Wiestler, O. Brustle, W. Mueller, C. Gieffers, O. Hill, M. Thiemann, M. Seedorf, N. Gretz, R. Sprengel, T. Celikel, and A. Martin-Villalba. 2009. The death receptor CD95 activates adult neural stem cells for working memory formation and brain repair. Cell Stem Cell 5:178-190.
9. Cuppen, E., M. van Ham, D. G. Wansink, A. de Leeuw, B. Wieringa, and W. Hendriks. 2000. The zyxin-related protein TRIP6 interacts with PDZ motifs in the adaptor protein RIL and the protein tyrosine phosphatase PTP-BL. Eur. J. Cell Biol. 79:283-293.
10. Desbarats, J., and M. K. Newell. 2000. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat. Med. 6:920-923.
11. Dey, N., H. E. Crosswell, P. De, R. Parsons, Q. Peng, J. D. Su, and D. L. Durden. 2008. The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res. 68:1862-1871.
12. Du, J., P. Bernasconi, K. R. Clauser, D. R. Mani, S. P. Finn, R. Beroukhim, M. Burns, B. Julian, X. P. Peng, H. Hieronymus, R. L. Maglathlin, T. A. Lewis, L. M. Liau, P. Nghiemphu, I. K. Mellinghoff, D. N. Louis, M. Loda, S. A. Carr, A. L. Kung, and T. R. Golub. 2009. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat. Biotechnol. 27:77-83.
13. E, S., Y. J. Lai, R. Tsukahara, C. S. Chen, Y. Fujiwara, J. Yue, J. H. Yu, H. Guo, A. Kihara, G. Tigyi, and F. T. Lin. 2009. Lysophosphatidic acid 2 receptor-mediated supramolecular complex formation regulates its antiapoptotic effect. J. Biol. Chem. 284:14558-14571.
14. Gupta, S. 2003. Molecular signaling in death receptor and mitochondrial pathways of apoptosis. Int. J. Oncol. 22:15-20.
15. Husain, N., E. A. Chiocca, N. Rainov, D. N. Louis, and N. T. Zervas. 1998. Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines. Acta Neuropathol. 95:287-290.
16. Ivanov, V. N., P. Lopez Bergami, G. Maulit, T. A. Sato, D. Sassoon, and Z. Ronai. 2003. FAP-1 association with Fas (Apo-1) inhibits Fas expression on the cell surface. Mol. Cell. Biol. 23:3623-3635.
17. Kassel, O., S. Schneider, C. Heilbock, M. Litfin, M. Gottlicher, and P. Herrlich. 2004. A nuclear isoform of the focal adhesion LIM-domain protein Trip6 integrates activating and repressing signals at AP-1- and NF-kappaB-regulated promoters. Genes Dev. 18:2518-2528.
18. Kischkel, F. C., S. Hellbardt, I. Behrmann, M. Germer, M. Pawlita, P. H. Krammer, and M. E. Peter. 1995. Cytotoxicity-dependent APO-1 (Fas/ CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14:5579-5588.
19. Kishi, Y., S. Okudaira, M. Tanaka, K. Hama, D. Shida, J. Kitayama, T. Yamori, J. Aoki, T. Fujimaki, and H. Arai. 2006. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J. Biol. Chem. 281:17492-17500.
20. Kleber, S., I. Sancho-Martinez, B. Wiestler, A. Beisel, C. Gieffers, O. Hill, M. Thiemann, W. Mueller, J. Sykora, A. Kuhn, N. Schreglmann, E. Letellier, C. Zuliani, S. Klussmann, M. Teodorczyk, H. J. Grone, T. M. Ganten, H. Sultmann, J. Tuttenberg, A. von Deimling, A. Regnier-Vigouroux, C. Herold- Mende, and A. Martin-Villalba. 2008. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 13:235-248.
21. Lai, Y. J., C. S. Chen, W. C. Lin, and F. T. Lin. 2005. c-Src-mediated phosphorylation of TRIP6 regulates its function in lysophosphatidic acid-induced cell migration. Mol. Cell. Biol. 25:5859-5868.
22. Lai, Y. J., W. C. Lin, and F. T. Lin. 2007. PTPL1/FAP-1 negatively regulates TRIP6 function in lysophosphatidic acid-induced cell migration. J. Biol. Chem. 282:24381-24387.
23. Li, L., L. H. Bin, F. Li, Y. Liu, D. Chen, Z. Zhai, and H. B. Shu. 2005. TRIP6 is a RIP2-associated common signaling component of multiple NF-kappaB activation pathways. J. Cell Sci. 118:555-563.
24. Mathew, S. J., D. Haubert, M. Kronke, and M. Leptin. 2009. Looking beyond death: a morphogenetic role for the TNF signalling pathway. J. Cell Sci. 122:1939-1946.
25. Matsumoto, N., R. Imamura, and T. Suda. 2007. Caspase-8- and JNK-dependent AP-1 activation is required for Fas ligand-induced IL-8 production. FEBS J. 274:2376-2384.
26. Meng, Y., S. Kang, J. So, S. Reierstad, and D. A. Fishman. 2005. Translocation of Fas by LPA prevents ovarian cancer cells from anti-Fas-induced apoptosis. Gynecol. Oncol. 96:462-469.
27. Mills, G. B., and W. H. Moolenaar. 2003. The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer 3:582-591.
28. Murthy, K. K., K. Clark, Y. Fortin, S. H. Shen, and D. Banville. 1999. ZRP-1, a zyxin-related protein, interacts with the second PDZ domain of the cytosolic protein tyrosine phosphatase hPTP1E. J. Biol. Chem. 274:20679-20687.
29. Muzio, M., A. M. Chinnaiyan, F. C. Kischkel, K. O'Rourke, A. Shevchenko, J. Ni, C. Scaffidi, J. D. Bretz, M. Zhang, R. Gentz, M. Mann, P. H. Krammer, M. E. Peter, and V. M. Dixit. 1996. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85:817-827.
30. Nomura, N., M. Nomura, K. Sugiyama, and J. Hamada. 2007. Src regulates phorbol 12-myristate 13-acetate-activated PKC-induced migration via Cas/ Crk/Rac1 signaling pathway in glioblastoma cells. Int. J. Mol. Med. 20:511-519.
31. Nozell, S., T. Laver, D. Moseley, L. Nowoslawski, M. De Vos, G. P. Atkinson, K. Harrison, L. B. Nabors, and E. N. Benveniste. 2008. The ING4 tumor suppressor attenuates NF-kappaB activity at the promoters of target genes. Mol. Cell. Biol. 28:6632-6645.
32. Ogasawara, J., R. Watanabe-Fukunaga, M. Adachi, A. Matsuzawa, T. Kasugai, Y. Kitamura, N. Itoh, T. Suda, and S. Nagata. 1993. Lethal effect of the anti-Fas antibody in mice. Nature 364:806-809.
33. Parlato, S., A. M. Giammarioli, M. Logozzi, F. Lozupone, P. Matarrese, F. Luciani, M. Falchi, W. Malorni, and S. Fais. 2000. CD95 (APO-1/Fas) linkage to the actin cytoskeleton through ezrin in human T lymphocytes: a novel regulatory mechanism of the CD95 apoptotic pathway. EMBO J. 19:5123-5134.
34. Peter, M. E., R. C. Budd, J. Desbarats, S. M. Hedrick, A. O. Hueber, M. K. Newell, L. B. Owen, R. M. Pope, J. Tschopp, H. Wajant, D. Wallach, R. H. Wiltrout, M. Zornig, and D. H. Lynch. 2007. The CD95 receptor: apoptosis revisited. Cell 129:447-450.
35. Peter, M. E., and P. H. Krammer. 2003. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 10:26-35.
36. Raj, G. V., J. A. Sekula, R. Guo, J. F. Madden, and Y. Daaka. 2004. Lysophosphatidic acid promotes survival of androgen-insensitive prostate cancer PC3 cells via activation of NF-kappaB. Prostate 61:105-113.
37. Reich, A., C. Spering, and J. B. Schulz. 2008. Death receptor Fas (CD95) signaling in the central nervous system: tuning neuroplasticity? Trends Neurosci. 31:478-486.
38. Sato, T., S. Irie, S. Kitada, and J. C. Reed. 1995. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 268:411-415.
39. Schreck, R., K. Albermann, and P. A. Baeuerle. 1992. Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells. Free Radic. Res. Commun. 17:221-237.
40. Stettner, M. R., W. Wang, L. B. Nabors, S. Bharara, D. C. Flynn, J. R. Grammer, G. Y. Gillespie, and C. L. Gladson. 2005. Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells. Cancer Res. 65:5535-5543.
41. Strasser, A., P. J. Jost, and S. Nagata. 2009. The many roles of FAS receptor signaling in the immune system. Immunity 30:180-192.
42. Takizawa, N., T. C. Smith, T. Nebl, J. L. Crowley, S. J. Palmieri, L. M. Lifshitz, A. G. Ehrhardt, L. M. Hoffman, M. C. Beckerle, and E. J. Luna. 2006. Supervillin modulation of focal adhesions involving TRIP6/ZRP-1. J. Cell Biol. 174:447-458.
43. Trauth, B. C., C. Klas, A. M. Peters, S. Matzku, P. Moller, W. Falk, K. M. Debatin, and P. H. Krammer. 1989. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245:301-305.
44. Wang, H., W. Zhang, H. J. Huang, W. S. Liao, and G. N. Fuller. 2004. Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab. Invest. 84:941-951.
45. Xia, Z. P., and Z. J. Chen. 2005. TRAF2: a double-edged sword? Sci. STKE 2005:pe7.
46. Xu, J., Y. J. Lai, W. C. Lin, and F. T. Lin. 2004. TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor. J. Biol. Chem. 279:10459-10468.
47. Yi, J., S. Kloeker, C. C. Jensen, S. Bockholt, H. Honda, H. Hirai, and M. C. Beckerle. 2002. Members of the zyxin family of LIM proteins interact with members of the p130Cas family of signal transducers. J. Biol. Chem. 277: 9580-9589.
48. Yonehara, S., A. Ishii, and M. Yonehara. 1989. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med. 169:1747-1756.
49. Zhao, M. K., Y. Wang, K. Murphy, J. Yi, M. C. Beckerle, and T. D. Gilmore. 1999. LIM domain-containing protein trip6 can act as a coactivator for the v-Rel transcription factor. Gene Expr. 8:207-217.